Takeda Pharmaceutical announced plans to cut about 4,500 jobs in fiscal year 2026 as part of a restructuring aimed at centralizing corporate functions and lowering expenses [1, 2]. The job reductions represent less than 10% of Takeda's global workforce [1, 2].
Despite the cuts, Takeda currently has roughly 2,200 open roles and expects to create new positions during fiscal 2026, with a priority on filling those roles internally [1, 2]. The restructuring is expected to generate annual savings exceeding 200 billion yen by fiscal 2028, with about 100 billion yen saved already in fiscal 2026 [1].
Takeda anticipates restructuring costs of around 170 billion yen for fiscal 2026, which are forecast to decline in the following years [1]. The company’s efforts follow challenges stemming from its $62 billion acquisition of Shire in 2019, which expanded Takeda’s global footprint but also increased its debt and operational complexity [1].
Takeda announced these restructuring plans and its financial outlook during its fourth-quarter earnings presentation on May 13, 2026 [1, 2]. The company will monitor progress and savings as it implements changes throughout the fiscal year.
